A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Gian Domenico Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J. H J Wokke, T. Dobbins

Research output: Contribution to journalArticlepeer-review

Abstract

To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

Original languageEnglish
Pages (from-to)583-586
Number of pages4
JournalNeurology
Volume51
Issue number2
Publication statusPublished - Aug 1998

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this